Is Quest Diagnostics Incorporated (DGX) a Buy, Sell, or Hold?
Quest Diagnostics Incorporated
NYSE:DGX
$206 USD
-$1.35 (-0.65%)
- Volume
- 865.88K
- Average Volume
- 911.5K
- Market Capitalization
- $22.8B
- P/E Ratio
- 22.46
- Dividend Yield
- 1.61%
- Price Target
- $225.00
- Year High
- $219.20
- Year Low
- $164.65
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.35
- Current Ratio
- $1.18
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | James E. Davis |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Current Symbol | DGX |
| CUSIP | 74834L100 |
| CIK | 0001022079 |
| Web | https://www.questdiagnostics.com |
| Phone | 973 520 2700 |
| Currency | USD |
| Employees | 57000 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.95 |
| Payout Ratio | 0.35 |
| Current Ratio | 1.18 |
| Quick Ratio | 1.08 |
| Cash Ratio | 0.18 |
Sales & Book Value
| Annual Sales | $11.04B |
| Price / Sales | 2.02 |
| Cash Flow | 12.05 |
| Price / Cash Flow | 17.20 |
| Price / Book | 3.08 |
Price Target and Rating
| Average Stock Price Forecast | $225.00 |
| High Stock Price Forecast | $236.00 |
| Low Stock Price Forecast | $210.00 |
| Forecast Upside/Downside | -8.44% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 34 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $8.75 |
| Trailing P/E Ratio | 22.46 |
| PEG Ratio | 1.55 |
| P/E Growth | 1.55 |
| Net Income | $992M |
| Net Margin | 9.08% |
| Pretax Margin | 12.41% |
| Return on Equity | 14.11% |
| Return on Assets | 6.14% |
Financials Score
| AltmanZ Score | 3.41 |
| Piotroski Score | 7.00 |
| Working Capital | 389M |
| Total Assets | 16.67B |
| Ebit | 1.66B |
| Market Cap | 22.95B |
| Total Liabilities | 9.01B |
Poll Results
About Quest Diagnostics Incorporated (NYSE:DGX) Stock
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated thro ... ugh a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Quest Diagnostics to Report Q2 Earnings: Key Customer Channels in Focus
2026-07-14 11:01:33
DGX's Q2 results may reflect growth across physician, hospital and consumer channels as AI tools and advanced diagnostics gain traction.
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
2026-07-10 10:41:17
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
2026-07-08 08:52:00
American Oncology Network (AON) and other community oncology providers launching now as part of a pilot program that provides access to Haystack MRD SECAUCUS, N.J., July 8, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it is integrating its Haystack MRD® ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers within OncoEMR®, an electronic health record (EHR) from Flatiron Health, via a pilot program with American Oncology Network (AON) and other community oncology providers.
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock
2026-07-06 10:51:09
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?
2026-07-02 10:16:05
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DGX's Stock Rises on Haystack MRD Test's Approval From NYSDOH
2026-06-25 11:31:06
Quest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states and strengthening its oncology reach.
Quest Diagnostics Inc (DGX) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 83/100
2026-06-24 18:12:00
On June 24, 2026, Quest Diagnostics Inc (DGX) shares rose 3.0% today, currently trading at $203.11. This performance places the stock well within its 52-week ra
2026-06-24 08:52:00
Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancers SECAUCUS, N.J., June 24, 2026 /PRNewswire/ -- Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers.
Frequently Asked Questions
-
What is the current Quest Diagnostics Incorporated (DGX) stock price?
-
Quest Diagnostics Incorporated(NYSE:DGX) stock price is $206 in the last trading session. During the trading session, DGX stock reached the peak price of $219.2 while $164.65 was the lowest point it dropped to. The percentage change in DGX stock occurred in the recent session was --0.65% while the dollar amount for the price change in DGX stock was -$-1.35.
-
DGX's industry and sector of operation?
-
The NYSE listed DGX is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of DGX?
-
Michael E. Prevoznik | Senior Vice President & General Counsel
Sam A. Samad | Executive Vice President & Chief Financial Officer
Catherine T. Doherty | Executive Vice President of Regional Businesses
Dan Haemmerle | Interim VP of Investor Relations & VP Finance
Garry Clark | Senior Vice President and Chief Marketing & Communications Officer -
How many employees does DGX have?
-
Number of DGX employees currently stands at 57000. DGX operates from 500 Plaza Drive, Secaucus, NJ 07094, US.
-
Link for DGX official website?
-
Official Website of DGX is: https://www.questdiagnostics.com
-
How do I contact DGX?
-
DGX could be contacted at phone #973 520 2700 and can also be accessed through its website. DGX operates from 500 Plaza Drive, Secaucus, NJ 07094, US.
-
How many shares of DGX are traded daily?
-
The average number of DGX shares traded daily for last 3 months was 911.5K.
-
What is the market cap of DGX currently?
-
The market value of DGX currently stands at $22.8B with its latest stock price at $206